{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T02:45:21Z","timestamp":1789181121436,"version":"build-2803163510"},"reference-count":15,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2012,2,21]],"date-time":"2012-02-21T00:00:00Z","timestamp":1329782400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Psychiatry Clin Neurosci"],"published-print":{"date-parts":[[2012,3]]},"abstract":"<jats:p><jats:bold>Aims:\u2002<\/jats:bold>Blonanserin is a second\u2010generation antipsychotic that was developed in Japan. We investigated the relationships between plasma concentration, the plasma anti\u20105\u2010HT<jats:sub>2A<\/jats:sub>activity\/anti\u2010D<jats:sub>2<\/jats:sub>activity (S\/D) ratio and extrapyramidal symptoms (EPS) in blonanserin dosing.<\/jats:p><jats:p><jats:bold>Methods:\u2002<\/jats:bold>The subjects were 29 outpatients with schizophrenia. We assessed EPS using the Drug\u2010Induced Extrapyramidal Symptoms Scale (DIEPSS). The plasma concentrations were measured by high performance liquid chromatography, and the plasma anti\u2010D<jats:sub>2<\/jats:sub>and anti\u20105\u2010HT<jats:sub>2A<\/jats:sub>activities were measured by [<jats:sup>3<\/jats:sup>H]\u2010spiperone and [<jats:sup>3<\/jats:sup>H]\u2010ketanserin radioreceptor assays.<\/jats:p><jats:p><jats:bold>Results:\u2002<\/jats:bold>The results revealed that there were significant correlations between both the plasma concentration and the DIEPSS total score (<jats:italic>P<\/jats:italic>\u2003&lt;\u20030.05). A negative correlative tendency was found between the S\/D ratio and the DIEPSS total score. Furthermore, the plasma concentrations were divided into a low plasma concentration group and a high plasma concentration group, and the S\/D ratios were divided into a low S\/D ratio group and a high S\/D ratio group. We then compared each group based on the DIEPSS total scores. The score in the high plasma concentration\u2010low S\/D ratio group was significantly higher than in the high plasma concentration\u2010high S\/D ratio, low plasma concentration\u2010high S\/D ratio and low plasma concentration\u2010low S\/D ratio groups (<jats:italic>P<\/jats:italic>\u2003&lt;\u20030.05 for all).<\/jats:p><jats:p><jats:bold>Conclusions:\u2002<\/jats:bold>These findings indicate that the incidence of EPS during treatment with blonanserin is mainly determined by plasma concentration, but the incidence of EPS may be inhibited when anti\u20105HT<jats:sub>2A<\/jats:sub>activity is predominant over anti\u2010D<jats:sub>2<\/jats:sub>activity.<\/jats:p>","DOI":"10.1111\/j.1440-1819.2011.02311.x","type":"journal-article","created":{"date-parts":[[2012,2,21]],"date-time":"2012-02-21T11:36:03Z","timestamp":1329824163000},"page":"146-152","source":"Crossref","is-referenced-by-count":11,"title":["The relationship between the plasma concentration of blonanserin, and its plasma anti\u2010serotonin 5\u2010HT<sub>2A<\/sub>activity\/anti\u2010dopamine D<sub>2<\/sub>activity ratio and drug\u2010induced extrapyramidal symptoms"],"prefix":"10.1111","volume":"66","author":[{"given":"Hidenobu","family":"Suzuki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keishi","family":"Gen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2012,2,21]]},"reference":[{"key":"e_1_2_5_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2004.12.028"},{"key":"e_1_2_5_3_2","doi-asserted-by":"publisher","DOI":"10.1002\/hup.1124"},{"key":"e_1_2_5_4_2","first-page":"241","article-title":"A study of risperidone induced extrapyramidal symptoms\u2010 Plasma Risperidone, 9\u2010OH Risperidone concentration and plasma anti 5\u2010HT2A activity\/anti\u2010D2 activity","volume":"4","author":"Yanagida H","year":"2001","journal-title":"Jpn. J. Clin. Psychopharmacol."},{"key":"e_1_2_5_5_2","first-page":"11","volume-title":"Commentary on the DIEPSS and Guide to Its Usage","author":"Inada T","year":"1996"},{"key":"e_1_2_5_6_2","unstructured":"InadaT YagiG GardosG.Inter\u2010rater reliability of the drug\u2010induced extrapyramidal symptoms scale (DIEPSS).Abstracts of 20th Collegium Internationale Neuropsycho\u2010Pharmacologicum Melbourne Australia 1996; 23\u201327.1996."},{"key":"e_1_2_5_7_2","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/S0022-3565(25)10246-2","article-title":"Pharmacological profile of AD\u20105423, a novel antipsychotic with both potent dopamine\u2010D2 and serotonin\u2010S2 antagonist properties","volume":"264","author":"Oka M","year":"1993","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"e_1_2_5_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2010.11.023"},{"key":"e_1_2_5_9_2","doi-asserted-by":"publisher","DOI":"10.1097\/WNF.0b013e3181dcda50"},{"key":"e_1_2_5_10_2","doi-asserted-by":"publisher","DOI":"10.2165\/00023210-200923070-00006"},{"key":"e_1_2_5_11_2","first-page":"2059","article-title":"Clinical evaluation of blonanserin for schizophrenia\u2010A randomized controlled study comparing blonanserin with haloperidol","volume":"10","author":"Murasaki M","year":"2007","journal-title":"Jpn. J. Clin. Psychopharmacol."},{"key":"e_1_2_5_12_2","first-page":"817","article-title":"An overview of clinical trials of blonanserin, a new antipsychotic drug with dopamine D2 and serotonin 5\u2010HT2A antagonism","volume":"11","author":"Ishigooka J","year":"2008","journal-title":"Jpn. J. Clin. Psychopharmacol."},{"key":"e_1_2_5_13_2","first-page":"855","article-title":"Preclinical and clinical features of blonanserin","volume":"11","author":"Murasaki M","year":"2008","journal-title":"Jpn. J. Clin. Psychopharmacol."},{"key":"e_1_2_5_14_2","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/S0031-6997(25)06671-2","article-title":"Effects of antipsychotic drugs on serotonin receptors","volume":"43","author":"Meltzer HY","year":"1991","journal-title":"Pharmacol. Rev."},{"key":"e_1_2_5_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.pnpbp.2003.09.010"},{"key":"e_1_2_5_16_2","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/S0022-3565(25)20710-8","article-title":"Classification of typical and atypical antipsychotic durgs on the basis of dopamine D\u20101, D\u20102 and serotonin 2 pki values","volume":"251","author":"Meltzer HY","year":"1989","journal-title":"J. Pharmacol. Exp. Ther."}],"container-title":["Psychiatry and Clinical Neurosciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1440-1819.2011.02311.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1440-1819.2011.02311.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,21]],"date-time":"2025-03-21T10:50:56Z","timestamp":1742554256000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1440-1819.2011.02311.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,2,21]]},"references-count":15,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2012,3]]}},"alternative-id":["10.1111\/j.1440-1819.2011.02311.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1440-1819.2011.02311.x","archive":["Portico"],"relation":{},"ISSN":["1323-1316","1440-1819"],"issn-type":[{"value":"1323-1316","type":"print"},{"value":"1440-1819","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,2,21]]}}}